EagleAlpha OP : my analysis of the expected return of its phase III pipeline shows a fair value of $160-170 (even with pessimistic bias).

EagleAlpha : Market expected profitability sooner, expected more expense cut, and quicker approval. Mission impossible.

EagleAlpha : Yes they do have a strong balance sheet but the market might think the mgt are too audacious and a bit concerned about the speed of cash burn for R&D (interestingly some risk takers punish sp today thinking they shouldn’t slow down). I’d like
them focusing on more promising ones. I hope 1083 can be successfully launched cos many would like to have flu-COVID combo shot. COVID demand may come back in 2025 because many didn’t get boosters in 2023 and 2024. Part of reason why the current demand is weak is because ppl either got COVID or had triple vaccinated two years ago, antibody still there but may not last long, plus virus itself is mutating.

EagleAlpha : they r not cutting enough r&d, and Keytrura combo therapy won’t get fast track approval. Market think it’s too audacious

EagleAlpha OP WinningTrader : Traders focus on price they pay, whilst contrarian investors care about value they get. I dislike Baidu cos it has no ethics but I hold my nose buying cos they know how to work with Chinese gov and they r laying foundation for big money. Not just robotaxi, Baidu is selling biz solutions to EV makers, among them (at least for the map part) there is Tesla. And I don’t care EV makers in China   making money or loss, as long as the market is crowded and everyone needs to install map and autopilot.

EagleAlpha : When RSV combines with covid and flu shot, it won’t be a disadvantage to just cover one season.  U will get 2-in-1 or 3-in-1 shot every year anyway. It’s sufficient and still a good vaccine, remember current flu shot last just 6 months with just 40-60% efficacy rate.